In compliance with current regulations, let us know which audience you belong to:
Espansione Group is pleased to announce new and promising preliminary results demonstrating the effectiveness of LM™ LLLT (Light Modulation™ Low-Level Light Therapy) in managing Dry Eye Disease (DED) and Intraocular Pressure (IOP) in patients with glaucoma. These findings, recently presented at ESCRS 2024, originate from two separate clinical trials conducted by leading ophthalmologists: Prof. M. A. Teus (Spain) and the joint research team of Prof. G. Giannaccare (Italy) and Dr. C. Sannace (Italy).
Dry Eye in Glaucoma Patients: Prevalence, Incidence, and Challenges
Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness worldwide. The management of glaucoma frequently involves chronic use of topical medications, such as prostaglandin analogs, which can lead to drug-induced iatrogenic DED.
According to recent studies, the prevalence of DED in glaucomatous patients ranges from 40% to 59%, with incidence increasing with the duration and complexity of glaucoma treatment regimens.
Patients with glaucoma and concurrent DED face unique challenges, including reduced adherence to treatment, decreased quality of life, and compromised visual outcomes. Managing DED effectively in these patients is crucial to optimizing both their ocular surface health and glaucoma therapy compliance.
Study Overview and Results—Prof. G. Giannaccare (Italy) & Dr. C. Sannace (Italy)
A prospective, randomized controlled clinical trial conducted by Prof. G. Giannaccare and Dr. C. Sannace in Italy assessed the effectiveness of LM™ LLLT for managing DED in patients with glaucoma. The study included 40 eyes from 20 patients, who received LM™ LLLT treatments twice weekly over three weeks. Key outcomes were measured before treatment initiation (T0) and four weeks after the final session (T1).
Key Outcomes
Study Overview and Results—Prof. M. A. Teus (Spain)
In a separate prospective interventional study, Prof. M. A. Teus (Spain) evaluated the impact of LM™ LLLT on the quality of life and ocular health of glaucoma patients undergoing chronic prostaglandin therapy. The study was accepted as an abstract during ESCRS 24. The trial included 35 eyes from 18 patients, with assessments conducted at baseline, one month, and three months post-treatment.
Key Outcomes
In Short
These preliminary results position LM™ LLLT as a valuable tool in the management of dry eye symptoms
and intraocular pressure in patients with glaucoma, potentially transforming current therapeutic approaches and opening new avenues for patient care.
About Espansione Group
Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.
The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.
Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.
For more information, see www.espansionegroup.it
Espansione Group Press Office
press@espansione.it
© 2024 Espansione Group, All Rights Reserved
Posted on September, 13th, 2024, in Newsroom